Form D · Biotechnology

Kalyra Pharmaceuticals, Inc.

San Diego, CA · CIK 0001584696

Offering snapshot reported Nov 8, 2013 · SEC filing

Reported sold
$6.18M
Offering amount: $7M
Investors reported
32
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 14, 2013
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$3.09M$6.18MAug 21, 2013: $5,172,879.00Aug 21, 2013Nov 8, 2013: $6,181,380.00Nov 8, 2013

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$5,172,879 → $6,181,380
  • Reported investors19 → 32

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 8, 2013Amendment$6,181,380$1,008,501vs Aug 21, 201332SEC filing
Aug 21, 2013Initial$5,172,879No comparison19SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-201695

Source: Form D, filed Nov 8, 2013. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael E. Breede Director
Kevin D. Bunker Director, Executive
Cam Gallagher Executive
Cam L. Garner Director
Scott L. Glenn Director
Ned A. Israelsen Director
Dirk A. Thye Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
6181 Cornerstone Court Suite 105 106
San Diego, CA, 92121